Psyence BioMed Secures Debt-Free PsyLabs Platform, Exports First Clinical Product to Australia
Psyence BioMed’s PsyLabs investment delivers a licensed, debt-free, GMP-compliant production operation with source-level ibogaine and natural psilocybin supply, fortified by integrated analytical and IP infrastructure. The first export of its clinical trial product to Australia validates the model’s operational readiness and reduces execution risk for its ongoing Phase IIb trial.
1. Vertical Integration Strengthens Manufacturing and Supply
Through its PsyLabs investment, Psyence BioMed has established a licensed, owned and debt-free production facility with GMP-compliant manufacturing capabilities, source-level ibogaine supply, natural psilocybin sourcing, integrated analytical laboratories and intellectual property protection, enhancing control over its pharmaceutical-grade supply chain.
2. First Clinical Trial Export Validates Platform
The recent export of PsyLabs’ first clinical trial product to Australia demonstrates operational and commercial readiness, materially reducing execution risk and supporting continuity for the ongoing Phase IIb adjustment disorder trial in palliative care.
3. Disciplined Capital Framework and Market Position
Operating with no corporate debt and a disciplined capital allocation framework focused on infrastructure and clinical advancement, the company is positioned to capture value in a global psychedelic drugs market projected to reach $8.75 billion by 2031 where GMP-compliant supply chains create high entry barriers.
4. Board Appointment Adds Regulatory and Operational Expertise
Following Seth Feuerstein’s resignation, the appointment of Sashank Pillay to the board brings expertise in psilocybin cultivation, production project execution, regulatory compliance and international logistics, strengthening oversight of manufacturing and supply operations.